검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Losartan |
Overview Company | OHSU Knight Cancer Institute |
Overview Modality | ADC |
Overview Target | FRα |
Overview Indication | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8 |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
MoA Mechanism | target key profibrotic pathway |
MoA Biomarker | biomarkers, oxidative stress markers, and fibrosis-related markers were analyzed using RT-qPCR, immunohistoch |
PK/PD Half-life | 2 h |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat, In vitro |
Toxicology Major finding | Exploring the neuroprotective potential of losartan against acrylamide-induced oxidative stress and apoptosis in PC12 cells.. Acrylamide (ACR), a potential neurotoxin, is produced during industrial and food processing. The mechanisms of ACR neurotoxicity are still under debate, and effective strategies need to be investigated. We examined the neuroprotective potential of losartan (LOS), an antihyp… |
Clinical PFS | 17.5 |
Clinical OS | 17.5 |
Clinical Result source | ClinicalTrials.gov NCT01821729 |
Clinical Data Tier / Score | A · 18 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Losartan |
Overview Company | OHSU Knight Cancer Institute |
Overview Modality | ADC |
Overview Target | FRα |
Overview Indication | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8 |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
MoA Mechanism | target key profibrotic pathway |
MoA Biomarker | biomarkers, oxidative stress markers, and fibrosis-related markers were analyzed using RT-qPCR, immunohistoch |
PK/PD Half-life | 2 h |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat, In vitro |
Toxicology Major finding | Exploring the neuroprotective potential of losartan against acrylamide-induced oxidative stress and apoptosis in PC12 cells.. Acrylamide (ACR), a potential neurotoxin, is produced during industrial and food processing. The mechanisms of ACR neurotoxicity are still under debate, and effective strategies need to be investigated. We examined the neuroprotective potential of losartan (LOS), an antihyp… |
Clinical PFS | 17.5 |
Clinical OS | 17.5 |
Clinical Result source | ClinicalTrials.gov NCT01821729 |
Clinical Data Tier / Score | A · 18 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교